MedTrace Logo

Retrospective Study of ImmunoFormulation for COVID-19

NCT04666753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-12-14

No results posted yet for this study

Summary

Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic test based on the duration of symptoms.

Conditions

  • Covid19

Interventions

DIETARY_SUPPLEMENT

ImmunoFormulation

The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).

Sponsors & Collaborators

  • Fagron Iberica S.A.U.

    lead INDUSTRY

Principal Investigators

  • Hudson Polonini, PhD · Global Innovation Project Manager

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-02
Primary Completion
2020-09-29
Completion
2020-09-29

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04666753 on ClinicalTrials.gov